To date, in lung cancer, early attempts to modulate the immune system via vaccine-based therapeutics have been unsuccessful. An improved understanding of tumor immunology has facilitated the production of more sophisticated lung cancer vaccines. It is anticipated that it will likely require multiple epitopes of a diverse set of genes restricted to multiple haplotypes to generate a truly effective vaccine that is able to overcome the various immunologic escape mechanisms that tumors employ. Other issues to overcome include optimal patient selection, which adjuvant agent to use, and how to adequately monitor for an immunologic response. This review discusses the most promising vaccination strategies for non-small cell lung cancer including the allogeneic tumor cell vaccine belagenpumatucel-L, which is a mixture of 4 allogeneic non-small cell lung cancer cell lines genetically modified to secrete an antisense oligonucleotide to transforming growth factor A 2 and 3 other target protein-specific vaccines designed to induce responses against melanoma-associated antigen A3, mucin 1, and epidermal growth factor.
L ung cancer remains the leading cause of cancer-related mortality, and up to one third of cancer-related deaths in the United States can be attributed to this disease. 1 Non-small cell lung cancer (NSCLC) accounts for 85% of newly diagnosed lung cancer cases, and most patients present with advanced or metastatic disease. 2 Surgical resection is the only truly curative therapy, but with relapse rates greater than 40% after definitive resection, improved therapeutics in the adjuvant setting are required. 3 In advanced stages of disease, systemic chemotherapy and/or localized irradiation can produce objective responses and palliation of symptoms; however, these therapies offer only modest improvements in survival. Two-year survival rates for stages IIIB and IV NSCLC are 10.8% and 5.4%, respectively; 5-year survival rates are 3.9% and 1.3%, respectively. 4 In theory, stimulating the immune system by inducing a cellular immune response that harnesses CD4+ and CD8+ cytotoxic T lymphocytes (CTLs) capable of selectively destroying cancer cells by targeting tumor-associated antigens (TAAs) should potentially result in tumor eradication. Efforts to date have met with limited success for a variety of reasons. These include ineffective priming of tumor-specific T cells, lack of high-avidity of primed tumor-specific T cells, and physical or functional disabling of primed tumor-specific T cells by the primary host and/or tumorrelated mechanisms. 5, 6 In NSCLC, a high proportion of the tumorinfiltrating lymphocytes are immunosuppressive T regulatory cells (CD4+ CD25+) that secrete transforming growth factor A (TGF-A) and express a high level of cytotoxic T-lymphocyte antigen-4. 7 These cells impede immune activation by facilitating T-cell tolerance to TAAs rather than cross-priming CD8+ T cells resulting in the nonproliferation of killer T cells that recognize the tumor without attacking it. 7Y9 Elevated levels of interleukin 10 (IL-10) and TGF-A are found in patients with NSCLC. Preclinical models have shown that immune suppression is mediated by these cytokines serving as a defense for malignant T cells against the body's immune system. 10Y12 Other tumor escape mechanisms include decrease or loss of tumor-specific antigen, down-regulation of expression of human leukocyte antigen molecules, and increased expression of immunosuppressive factors by cancer cells including regulatory T cells and tolerant dendritic cells (DCs).
Current vaccine approaches focus on coupling immunogenic adjuvant agents to tumor antigens. The adjuvant agents are typically mixed with tumor cells or tumor antigens, and the admixture is then used to vaccinate patients. Adjuvant agents enhance the antigen-presenting cell (APC) response to the vaccine. The APCs then present antigen to T cells resulting in the activation of tumor-specific T cells. Attempts have been made to strengthen the immune response by incorporating naturally secreted immune modulators into vaccines. Strategies include genetically modifying autologous tumor cells or allogeneic cell lines to secrete cytokines and/or costimulatory molecules. Another way to boost the immune system is by expressing the antigen in a viral vector, which can also be designed to encode costimulatory molecules or cytokines. Other approaches include priming the immune system by using vaccines containing autologous DCs loaded with tumor antigen to elicit a tumor-specific CTL response.
Herein we discuss the most advanced therapies that are in the latter stages of development for NSCLC including the wholecell vaccine, belagenpumatucel-L, and target protein-specific vaccines against melanoma-associated antigen A3 (MAGE-A3), epidermal growth factor (EGF), and mucin 1 (MUC1).
BIOLOGIC RATIONALE FOR USING VACCINES IN NSCLC
The primary aim of vaccine therapy is to provoke an adaptive antitumor immune response. 13, 14 The first step in the cellular immunity cascade begins with the uptake of antigen, delivered by the vaccine, by APCs such as DC or macrophages. Once internalized, short peptide sequences of the antigen are presented on the extracellular surface of the APC in conjunction with the major histocompatibility complex (MHC) molecules. Dendritic cells then move from the periphery to the lymph nodes where they meet naive T lymphocytes. 15 Complex reactions involving the specific T-cell receptor and the APC MHC peptide molecule, as well as activation of costimulatory molecules such as B7.1 and B7.2, are required to activate CD8+ CTLs. 16 Once activated, these CTLs circulate and recognize cells that display the complementary peptide MHC class I molecule on the cell surface. Cell death occurs via a combination of either granule exocytosis or expression of the FAS ligand, which ultimately leads to apoptosis. 17 Activation of CD4+ T cells leads to the secretion of a wide range of cytokines including IL-2 and interferon F, which in turn facilitate the activation of cognate CD8+ cytotoxic T cells that recognize the target peptide bound to MHC class 1 receptors. Activation of CD4+ T cells also enhances the killing activity of natural killer cells and the phagocytic activity of macrophages and triggers a humoral immune response leading to antibody production.
Unfortunately, most cancer cells can evade the immune system by a variety of different mechanisms. 18, 19 These include down-regulation of the expression of target antigens, MHC, or costimulatory molecules, such as B7.1 or B7.2, on initial antigen presentation leading to a failure of T-cell recognition. Tumor cells also evade the immune system by down-regulating immune cytokines and developing resistance to CTLs. Lung cancer cells have been shown to produce a variety of immunosuppressive molecules including TGF-A, prostaglandin E 2 , IL-10, and cyclooxygenase 2 that can affect DC processing and presentation, as well as the acquisition and expression of CTL effector cell function. 18Y20 Strategies to develop effective immunotherapy for lung cancer have, in the past, failed. Recent successes in identifying T-cell responses to tumor-specific antigens in patients with lung cancer suggest that this goal may now be achievable. 21 The identification of lung TAAs and presenting them in the optimal context may enable the immune system to generate antilung tumor effector cells. 22 
Allogeneic Tumor Cell Vaccines

Belagenpumatucel-L (Lucanix)
Transforming growth factor A has a tumor-associated immunosuppressive role via its inhibition of both natural killer cells and DCs. 23, 24 Many tumors, including lung cancer, produce high levels of latent and active TGF-A, and elevated levels have been identified as a poor prognostic factor in NSCLC. 25, 26 A number of T cellY and DC-associated mechanisms have been proposed to explain the activity of TGF-A, including impairment of high-affinity IL-2 receptor function and expression, leading to inhibition of CTL activation. 27 Transforming growth factor A 2 is also able to convert naive T cells to T regulatory cells by inducing the transcription factor FOXP3. 28 T regulatory cells specifically prevent immune activation. 29 Dendritic cells play a crucial role in the induction of antitumor immunity in tumorbearing hosts by a process of antigenic cross-presentation. 30 Immature DCs are unable to stimulate potent immune responses. Transforming growth factor A 2 can block maturation of DCs and inhibit their ability to present antigens. 31 The vaccine belagenpumatucel-L (Lucanix) is a mixture of 4 allogeneic NSCLC cell lines genetically modified to secrete an antisense oligonucleotide to TGF-A 2 . The rationale for using a cell cocktail vaccine is based on the observation that NSCLC tumor cell lines share immunogenic epitopes with primary tumors. Major histocompatibility complex class IYrestricted CTLs generated against a specific human lung adenocarcinoma cell line have exhibited demonstrable cytotoxicity against other lung cancer cell lines. To increase the array of tumor antigens presented in the vaccine, belagenpumatucel-L uses 4 cell lines that express low levels of TGF-A due to prior transfection with a TGF-A 2 antisense plasmid. It is anticipated that down-regulation of TGF-A expression in the vaccine will mitigate a major source of immune suppression at the vaccine injection site. The hypothesis is that injecting allogeneic tumor cells with downregulated TGF-A 2 will enhance local immune recognition and activation of effector cells, leading to a systemic immune response capable of targeting the patient's native tumor.
In a randomized phase II trial, 32 75 patients with stage II to IV NSCLC were randomized to intradermal (ID) injections of 1 to 3 dose levels (1.25 Â 10 7 cells/injection, 2.5 Â 10 7 cells/ injection, or 5.0 Â 10 7 cells/injection) on a monthly or everyother-month schedule to a maximum of 16 injections. No significant adverse events were reported, and a dose-related survival difference was demonstrated in patients who received 2.5 Â 10 7 cells or more per injection (P = 0.0155). Analysis suggested that cohorts 2 and 3, who received doses 2.5 Â 10 7 cells or more per injection, had a significant survival advantage compared with cohort 1 (P = 0.0069). Of the 61 patients with late-stage NSCLC (IIIB/IV), 15% had a partial response. The estimated probabilities of surviving 1 and 2 years were 68% and 52%, respectively, for the higher-dose groups combined, and 39% and 20%, respectively, for the low-dose group. The estimated median survival for patients receiving 2.5 Â 10 7 cells or higher per injection was 581 days compared with 252 days for patients receiving 1.25 Â 10 7 cells per injection (P = 0.0186). The difference in overall survival between dose cohorts 1, 2, and 3 in stage III/IV patients was not statistically significant (P = 0.5148). Increased cytokine production (interferon F, P = 0.006; IL-6, P = 0.004; and IL-4, P = 0.007) was observed among clinical responders (partial response or stable disease) who also displayed an elevated antibody-mediated response to the vaccine (P = 0.014). The results of this early phase clinical trial are intriguing. The phase II trial results certainly seem promising, but the small number of patients and the possibility of selection bias suggest that the early results need to be compared to a control arm in a randomized trial.
A phase III investigation (STOP trial) is ongoing, evaluating the vaccine as a maintenance therapy in patients with unresectable stage III/IV NSCLC who have responded to or have stable disease after first-line platinum-based chemotherapy. Its primary end point was to compare the overall survival of subjects treated with belagenpumatucel-L versus those treated with placebo. The course of therapy in the treatment arm is best supportive care (BSC) plus monthly ID injections of belagenpumatucel-L consisting of 25,000,000 cells in a volume of 0.40 mL once a month for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity. The study commenced in July 2008 and is expected to enroll 506 patients by October 2012. The estimated primary completion date is June 2012.
Autologous Tumor Cell Vaccines
Cell Suspension of Whole Tumor Transfected With Granulocyte Macrophage Colony Stimulating Factor
GVAX is a vaccine composed of whole tumor cells genetically modified to secrete granulocyte macrophage colony stimulating factor (GM-CSF). The initial vaccine used autologous irradiated tumor cells transfected with a nonreplicating adenoviral vector engineered to secrete GM-CSF. 33 In the phase I trial involving patients with stage IV NSCLC, the vaccine was well tolerated, with toxicities restricted to grade 1 and 2 local skin reactions. The vaccine demonstrated activity, with 5 patients having stable disease and 2 patients with no demonstrable disease (having had surgical resection of all known metastatic sites before vaccination) achieving prolonged remissions of more than 40 months. On the basis of these promising results, a larger phase I/II trial was reported in 2004. 34 This trial consisted of 2 cohorts: patients with stage IB or II NSCLC and patients with stage III or IV disease. Only 43 of 83 patients who underwent tumor harvest were treated, of whom 33 had advanced disease. Three of the 33 advanced-stage patients (2 of whom had bronchioloalveolar carcinoma) had durable complete responses lasting 6, 18, and 22 months or longer. Interestingly, secretion of GM-CSF after vaccination was shown to correlate with outcome. A longer survival was observed in patients receiving vaccines secreting GM-CSF at more than 40 ng/24 h per 10 6 cells (median survival, 17 months; 95% confidence interval [CI], 6Y23 months) than in patients receiving vaccines secreting less GM-CSF (median survival, 7 months; 95% CI, 4Y10 months) (P = 0.028). The results of this study suggested a vaccine doseYrelated survival advantage.
A subsequent trial evaluated unmodified tumor cells combined with an allogeneic bystander cell line (K562, human erythroleukemia cell line) genetically modified to secrete higher levels of GM-CSF. The combination is referred to as bystander GVAX. This vaccine does not require genetic modification of individual autologous tumor cell preparations and provides substantially higher and more consistent GM-CSF secretion. Fortynine patients with stage IIIA to IV NSCLC received vaccine, but unlike in the previous study, none achieved a partial or complete tumor response. 35 There is speculation that derivation from a bystander cell line may detract from GM-CSF's ability to boost immune responses against the TAA by the induction of myeloid suppressor cells and associated impairment of antigen-specific T-cell responses. It has been concluded that GM-CSF has to be secreted by the tumor cell itself or as recombinant purified protein.
Recent data from phase III clinical trials using this approach in other cancer settings have not demonstrated improved survival compared with standard chemotherapy leading to uncertainty of the future of this platform.
Protein-Specific Vaccines
Melanoma-Associated Antigen A3
Melanoma-associated antigen is a TAA expressed in cancer cells. MAGE is not expressed in normal tissue, except in male germ cell lines, which are devoid of MHC molecules and are therefore unable to present MAGE-A antigens. 36, 37 Melanomaassociated antigen A3 is the most silent gene in germline cells within the MAGE-A family and is considered a promising immunotherapy target. 38 It is expressed in 35% of NSCLC, and the rate of expression increases as the disease spreads (30% of stage I patients and 50% of stage II patients express MAGE-A3 in their primary tumors). Its expression is thus associated with poor prognosis. 39, 40 A randomized phase II trial in 182 patients with completely resected stage IB or II MAGE-A3+ NSCLC comparing postoperative injections of MAGE-A3 recombinant protein combined with an adjuvant system (every 3 weeks Â 5 followed by every 3 months Â 8) versus placebo has been reported ( Table 1) . 41 After a median follow-up of 28 months, disease-free survival and overall survival hazard ratios (HRs) were 0.73 (95% CI, 0.45Y1.16) and 0.66 (95% CI, 0.36Y1.20), respectively, in favor of the MAGE-A3 group. None of the outcome end points reached statistical significance; however, the signal with respect to survival benefit was considered strong enough to warrant a phase III evaluation. A recent article reported an analysis of gene expression profiling of tumors before treatment to identify a predictive signature that correlates with clinical activity of MAGE-A3 antigen-specific immunotherapy. 42 In the overall population with resected stage IB/II NSCLC, MAGE-A3 treatment decreased the relative risk of recurrence by 25% (HR, 0.75; 95% CI, 0.46Y1.23). In the population with the predictive gene signature, MAGE-A3 treatment decreased the relative risk of recurrence by 43% (HR, 0.57; 95% CI, 0.25Y1.34).
The MAGRIT (MAGE-A3 as Adjuvant Non-Small Cell Lung Cancer Immunotherapy) study is currently recruiting in 33 countries, with 2270 patients with resected stage IB to IIIA MAGE-A3+ NSCLC expected to enroll. After adjuvant chemotherapy, patients are randomly assigned to receive 13 intramuscular injections of vaccine (GSK1572932A) or placebo during a 27-month period, with disease-free survival as the primary end point. The trial registry does not define the type of adjuvant chemotherapy. The study commenced in October 2007 and is ongoing.
Epidermal Growth FactorYBased Vaccines
Epidermal growth factor and its cell membrane receptor (EGFR) are known to be overexpressed in many epithelial tumors, including lung cancer. In the last decade, several smallmolecule inhibitors of EGFR-associated tyrosine kinases and monoclonal antibodies targeting EGFR have been developed. 43 Strategies targeting EGF using immunotherapeutics are also currently in development.
A vaccine consisting of human recombinant EGF conjugated to the carrier protein P64K, derived from Neisseria meningitides, was evaluated in 3 pilot clinical trials, and a pooled analysis accruing a total of 83 patients with stage IIIB/IV NSCLC was performed (Table 1) . 44 Alum and Montanide ISA51 have been used as vaccine adjuvants. In one study, a single dose of 45 conducted a randomized phase II controlled trial of a human recombinant EGF-based vaccine (CIMAvax) in patients with stage IIIB/IV NSCLC who had completed first-line chemotherapy. Eighty patients were randomly assigned to receive BSC or EGF vaccine. The vaccine dose contained 50-Kg equivalents of EGF, and the vaccine was administered on days 1, 7, 14, and 28 and then monthly thereafter. Serum EGF concentrations were reduced in 64.3% of patients receiving the vaccine, indicating an immune-mediated decrease in circulating EGF. When comparing vaccinated patients (n = 37) with controls (n = 37), the median overall survival showed a nonsignificant trend toward a survival advantage (6.5 vs 5.3 months, P = 0.098). In the subset of vaccinated patients 60 years or younger (n = 22) versus controls (n = 28), survival was significantly longer (11.6 vs 5.3 months, P = 0.0124). The vaccination was safe and well tolerated. There was a direct correlation between GAR and survival and between decreased serum EGF and survival. Both of these parameters have been proposed as markers to optimize vaccine dosage and schedules in future clinical trials. Clinical trials to reevaluate this approach in a larger patient series are ongoing in Cuba.
Mucin 1
Mucin 1 is a mucinous transmembrane glycoprotein that is overexpressed and underglycosylated or aberrantly glycosylated in many human malignancies. It is normally restricted to the apical surface of polarized epithelial cells, including those of the respiratory tract. 46 In many epithelial malignancies, MUC1 is overexpressed and loses its polarity of expression. 47 Mucin 1 has a large NH 2 -terminal ectodomain that becomes underglycosylated or aberrantly glycosylated, with shortened carbohydrate side chains, unmasking epitopes on its peptide core that can act as tumor-associated neoepitopes. The precise role of MUC1 in promoting tumor cell growth and survival is unclear, but it is thought to be involved in tumorigenicity, tumor cell migration, and increased resistance to stress-induced apoptosis of chemotherapeutic agents. 48Y51 High serum levels of MUC1 are associated with immune suppression and poor prognosis in patients with advanced adenocarcinoma. 52, 53 It is thought that cells that overexpress tumorassociated MUC1 may escape a strong host immune response, making MUC1 an attractive target for cancer immunotherapy.
BLP25 liposome vaccine (L-BLP25) targets the exposed core peptide of the MUC1 TAA. L-BLP25 is a lyophilized preparation consisting of BLP25 lipopeptide, immunoadjuvant monophosphoryl lipid A, and 3 lipids (cholesterol, dimyristoyl phosphatidylglycerol, and dipalmitoyl phosphatidylcholine), forming a liposomal product. 54 The vaccine is designed to induce a cellular immune response that may lead to immune rejection of tumor tissues that express the MUC1 antigen.
A randomized phase IIB trial of L-BLP25 in patients with stage IIIB/IV NSCLC after stable disease or response to pri-mary chemotherapy has been completed. 54 L-BLP25 was given weekly for 8 weeks (administered at 4 different sites to improve vaccine uptake in draining lymph nodes), with the option to proceed to maintenance therapy consisting of vaccination every 6 weeks starting in week 13. All patients received a single infusion of cyclophosphamide 300 mg/m 2 3 days before vaccine administration, which has been shown to reduce the activity of suppressor T cells. The study was powered to detect a 5-month difference in survival (HR, 0.583), with a power of 80% and one-sided P G 0.25. There were 88 patients in the vaccination arm and 83 in the BSC arm. Treatment was well tolerated, with 96.6% of patients in the vaccine arm completing the planned 8 injections and 69.3% proceeding to the maintenance phase. The most common adverse events were grade 1 flulike symptoms, events related to cyclophosphamide administration, and mild injection site reactions. T-cell proliferation assays were performed at baseline and during immunization. Of 78 samples evaluated, 16 demonstrated an antigen-specific T-cell response. The median overall survival was 17.4 months for the vaccination arm versus 13.0 months with BSC, a difference that did not reach statistical significance (P = 0.066, unadjusted Cox). The 2-year survival rate was 43.2% for the L-BLP25 arm versus 28.9% for the BSC arm. The greatest difference in survival was observed in patients with stage IIIB locoregional disease (adjusted HR, 0.524; 95% CI, 0.261Y1.052; P = 0.069). In this post hoc analysis by stage, patients with stage IIIB disease with malignant pleural effusion and stage IV disease (60.2%) showed overlapping survival curves. The reason why vaccine treatment seems to benefit only patients with locoregional IIIB (39.8%) disease is probably related to immune resistance mechanisms that are more active in advanced disease, although this hypotheses needs to be confirmed. In a recently reported study with a median followup of 53 months, the updated observed 2-year survival rate for patients with stage IIIB locoregional disease was 60% (median survival, 30.6 months) for the L-BLP25 arm versus 36.7% for the BSC arm (median survival, 13.3 months; P = 0.16). 55 Although this represents a subgroup analysis with a nonsignificant P value, the magnitude of the difference and its durability for an extended period suggests that further studies are warranted.
A multicenter, phase III, randomized, double-blind, placebocontrolled study of the cancer vaccine Stimuvax (L-BLP25 or BLP25 liposome vaccine) in NSCLC subjects with unresectable stage III disease is currently recruiting. The START (Stimulating Targeted Antigenic Responses To NSCLC) trial is expected to recruit 1476 patients who have had a response or have stable disease after at least 2 cycles of definitive platinum-based chemoradiation. The study commenced in December 2006 and is expected to reach its estimated enrollment by September 2014. After randomization, subjects in the investigational arm will receive, within 3 days of their treatment assignment, a single intravenous infusion of 300 mg/m 2 (to a maximum of 600 mg) cyclophosphamide 3 days before the first L-BLP25 vaccination. Subjects then receive 8 consecutive weekly subcutaneous vaccinations with 930 Kg of L-BLP25 (primary treatment phase) at weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by vaccinations with L-BLP25 at 6-week intervals, commencing at week 13 (maintenance treatment phase) until disease progression.
IDM-2101: 10-Epitope CTL Vaccine
Tumors express a wide variety of TAAs and have a potential for TAA loss. In addition, patients have differing T-cell repertoires, suggesting that a successful vaccine may need to incorporate a wide selection of CTL specificities. The IDM-2101 vaccine was designed to overcome these potential difficulties by inducing CTL responses against 5 TAAs frequently overexpressed in NSCLC: carcinoembryonic antigen (CEA), p53, HER2/neu, and MAGE-2 and -3. 56 IDM-2101 is composed of 10 synthetic peptides from these TAAs, 9 of which represent CTL epitopes. The tenth is a pan-DR epitope designed to augment the CTL response. 57 A phase II study investigated the efficacy of IDM-2101 in 63 human leukocyte antigen A2+ patients with metastatic NSCLC (Table 1 ). 56 One-year survival for the treated group was 60%, and the median survival was 17.3 months. One patient had a complete response and another had a partial response. A phase III validation trial in patients with advanced NSCLC is anticipated.
DC Vaccines
Some investigators have suggested that targeting tumor antigens alone may not elicit a strong enough immune response to be of therapeutic benefit. The discovery of DCs as professional APCs heralded their use in the development of cancer vaccines. 58 It has been proposed that manipulating DCs as a vaccine adjuvant may be an effective way to stimulate antitumor immunity and overcome tolerance. The principal purpose of DC-based immunotherapy is to induce an antigenspecific immune response. 59 Once stimulated by maturation factors such as inflammatory cytokines, or via CD40, DCs upregulate adhesion and costimulatory molecules to become terminally differentiated stimulators of T-cell immunity. 60 The effector arms of this antitumor response are CD4+ and CD8+ cells, which can only become activated against antigens when presented by APCs. 59 On administration of a DC-based vaccine, the DCs should migrate to secondary lymphoid organs and induce an antigenspecific immune response. 61, 62 In the small phase I/II trials of DC vaccines in patients with NSCLC that have been reported, the most common antigen used has been CEA, 63Y68 a glycoprotein that acts as an adhesion molecule and is overexpressed in 70% of NSCLC. 69 Human leukocyte antigenYrestricted class I CEA peptides or altered peptides were used as antigens in these studies, as the CEA peptide must be modified for effective immunogenicity.
Hirschowitz et al 70 reported a study of 16 patients with NSCLC ranging from stage IA to IIIB who received DC-based vaccines. The objectives of the study were to evaluate tolerability and measure immunologic responses in a heterogeneous group of NSCLC patients. Autologous DCs generated ex vivo from monocyte precursors (CD14+) were loaded with apoptotic bodies from an allogeneic adenocarcinoma cell line that overexpressed the TAAs HER2/neu, CEA, Wilms tumor 1, MAGE-2, and survivin. Two doses of vaccine consisting of 8 to 9 Â 10 7 cells were administered intradermally 1 month apart. Immune reactivity measured in vitro showed 3 distinct patterns: 5 of 16 patients showed no measurable immune reactivity, 5 showed reactivity to autologous DCs in the absence of tumor antigen (tumorindependent response), and 6 showed a tumor-specific immune response. Immunologic responses were independent of stage and prior therapy. There was no correlation between immune response and clinical outcome. In a continuation of the study, 14 additional patients were given the vaccine. 71 This study evaluated immunologic responses to immature, antigen-pulsed autologous DC vaccines in 2 distinct groups of NSCLC patients. Seven patients had undergone surgical resection (stage I/II) with or without adjuvant therapy, and 7 had unresectable stage III disease and were treated with chemoradiation alone. Four of the 7 patients with stage III unresectable disease and 6 of the 7 patients with stage I/II surgically resectable disease, including 3 of 3 patients who resection and also received adjuvant chemoradiation, demonstrated immune responses to the vaccine. No clear indication of therapeutic efficacy was noted.
In another study, patients with NSCLC were vaccinated with DCs loaded with MUC1 peptides or tumor lysate. 72 A survival advantage was observed in vaccinated patients whose tumors were found to express MUC1 compared with patients with MUC1-negative tumors (16.75 vs 3.8 months, P = 0.0101). In this study, DCs from 14 patients with advanced or metastatic breast or lung cancer (9 positive for MUC1 and 5 negative for MUC1) were loaded with MUC1 antigens or tumor lysate and used for therapeutic vaccination. Clinically, effects such as reduction in tumor sizes or tumor marker levels or disappearance of malignant pleural effusion were observed in 7 of the 9 MUC1-positive cases. All of the patients who exhibited partial responses were vaccinated with peptides rather than tumor lysate. Additional studies are required to fully elucidate the potential of this approach.
To achieve a greater immune response through better antigen presentation, researchers have used different mechanisms of delivering vaccine to APCs. Morse et al added antigen directly to ex vivoYgenerated DCs via an engineered fowlpox virus that expressed full-length CEA and TRICOM, an adjuvant agent consisting of 3 costimulatory molecules: B7.1, intracellular adhesion molecule 1, and lymphocyte function-associated antigen 3. 66 Only 3 of 14 patients enrolled had NSCLC. T-cell responses were induced in 10 (71%) of 14 patients, with 5 having stable disease for 3 months. The authors did not report the responders' underlying disease. Another study used a modified vaccinia virus engineered to express the entire MUC1 gene to vaccinate patients with advanced cancer expressing MUC1. 73 Three of 14 patients enrolled had NSCLC. Of the 14, 4 had stable disease for 6 to 9 months and 5 had an induced T-cell response.
CONCLUSIONS
Until recently, NSCLC was considered nonimmunogenic or poorly immunogenic. Several hypotheses explaining the lack of potency for vaccines in lung cancer include an ineffective priming of tumor-specific T cells, lack of high avidity of primed tumor-specific T cells, and physical or functional disabling of primed tumor-specific T cells by the primary host and/or tumorrelated mechanisms. At present, there are limited data from trials showing a clear clinical benefit for vaccines in lung cancer. One explanation may be that a measurable immune response does not translate into a clinically meaningful response. Patient selection may also be a problem for ongoing clinical studies. Most of these trials are focused on patients with advanced stage disease, whereas the ideal candidates for lung cancer vaccines may be patients with stage I or II disease who are considered at high risk of recurrence after resection. Selecting the optimal tumor antigens to target is also problematic. A truly effective therapeutic lung cancer vaccine may require multiple epitopes of a diverse set of genes restricted to multiple haplotypes to combat the various tumor escape mechanisms. Despite the multiple negative clinical trials, there are encouraging signs from several newer agents. Their role in the management of patients with NSCLC will be defined by the results of ongoing randomized phase III trials. As with targeted agents, it is likely that immunotherapy will only work for a select number of patients, and as such, the development of predictive biomarkers to allow for optimal patient selection is as important the development of effective vaccination strategies. It is unlikely that only one modality of treatment will be used in the future, and a combination of multiple immunologically active agents in addition to conventional
